范可尼贫血患者的口腔癌前病变与恶性病变
回顾性队列研究纳入2007至2021年四分转诊中心的105例范可尼贫血(FA)患者,平均就诊年龄11.3岁,90.5%接受造血干细胞移植(HSCT)。8.6%出现白斑或红斑,3.8%发生恶性肿瘤,头颈恶性肿瘤标准化发病比为483.8。作者结论认为FA患者应自10岁或HSCT后开始头颈癌筛查。
要点
- 105例FA患者中8.6%有白斑或红斑,3.8%发生恶性肿瘤。
- 头颈恶性肿瘤标准化发病比为483.8。
- 白斑和恶性肿瘤平均诊断年龄分别为14.6岁和25.1岁。
核心结论
- 范可尼贫血患者应自10岁或造血干细胞移植后开始头颈癌筛查。
研究设计与样本
- 回顾性队列研究,纳入2007至2021年四分转诊中心的105例范可尼贫血患者,评估头颈癌风险。
主要发现
- 患者平均就诊年龄11.3岁,90.5%接受造血干细胞移植。
- 8.6%的患者有白斑或红斑,3.8%发生恶性肿瘤。
- 头颈恶性肿瘤标准化发病比为483.8。
- 白斑和恶性肿瘤的平均诊断年龄分别为14.6岁和25.1岁。
- 恶性肿瘤具有侵袭性并以复发为特征;柔性喉镜检查未发现癌前或恶性病变。
临床怎么用
- 作者结论认为范可尼贫血患者应自10岁或造血干细胞移植后开始头颈癌筛查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is a lack of data supporting cancer surveillance in pediatric Fanconi Anemia patients. We sought to describe the rates of upper aerodigestive lesions and malignancy in this population to augment current management guidelines. METHODS: A retrospective cohort study of patients with Fanconi Anemia from a quaternary referral center between 2007-2021 was completed for head and neck cancer risk. RESULTS: One hundred and five FA patients were reviewed. Average age at presentation was 11.3 years old and 90.5% of patients underwent hematopoietic stem cell transplant (HSCT). A total of 8.6% of patients had leukoplakia or erythroplakia and 3.8% developed malignancy. The standardized incidence ratio of head and neck malignancy was 483.8. Patients presented with leukoplakia and malignancy at an average age of 14.6 and 25.1 years old, respectively. Malignancies were aggressive and marked by recurrence. There were no premalignant or malignant lesions found on flexible laryngoscopy. This series represents the largest longitudinal series of pediatric FA head and neck lesions. CONCLUSIONS: Fanconi Anemia patients should begin screening for head and neck cancer at age 10 or after HSCT. LEVEL OF EVIDENCE: Level 4 Laryngoscope, 133:1745-1748, 2023.
引用
- Archibald H, Kalland K, Kuehne A, et al. Oral Premalignant and Malignant Lesions in Fanconi Anemia Patients. Laryngoscope. 2022. PMID: 36054728. doi:10.1002/lary.30370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。